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1. Introduction 
The quality of life (QOL) of persons affected by generalized anxiety disorder (GAD), a 
condition characterized by periods of excessive anxiety and worry (American Psychiatric 
Association 1994), is significantly impaired, with an established link between GAD and 
impairment in a variety of areas (Henning et al. 2007). GAD is associated with increased 
self-reported disability days and impairments in psychosocial functioning, role functioning, 
work productivity, and QOL (Massion et al. 1993; Kessler et al. 1999; Wittchen et al. 2000; 
Kessler et al. 2001; Kessler and Wittchen 2002; Wittchen 2002). Consequently, 
comprehensive evaluations of treatment for GAD must include both clinical endpoints (i.e., 
Hamilton Anxiety Scale-Anxiety [HAM-A]) and assessments of patient-reported QOL and 
functioning. Moreover, it has been estimated that 92.1% of individuals with GAD also have 
another lifetime comorbid psychiatric disorder (Ruscio et al. 2007). Anxiety and depression 
often co-occur, and it has been proposed that a search for one condition should be 
accompanied by an assessment of the other (Kroenke et al. 2007). The inclusion of patient-
reported outcomes (PROs) in clinical development programs for GAD treatments will 
provide useful information for clinicians and their patients about the benefits of treatment 
on patient functioning and well-being, and the relationship between GAD and depression.  
The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), in both the long 
and short form (Q-LES-Q(SF)), is a widely used instrument for measuring QOL and 
satisfaction. Originally developed for use in clinical trials and among trial participants with 
a wide variety of mental and medical diseases or disorders (Endicott et al. 1993), it has been 
shown to offer high internal consistency, validity and reproducibility in non-psychiatric 
populations and in patients with a range of psychiatric illnesses (Endicott et al. 1993; Ritsner 
et al. 2005; Rossi et al. 2005; Endicott et al. 2006; Schechter et al. 2007; Mick et al. 2008; 
Revicki et al. 2008). Thus, the Q-LES-Q(SF) is a PRO measure that has the potential to extend 
and complement clinical efficacy endpoints and demonstrate the impact of alleviating GAD 
symptoms on patients’ everyday functioning. To date, few published studies have examined 
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the validity of Q-LES-Q(SF) in GAD (Endicott et al. 2007; Demyttenaere et al. 2008; Revicki 
et al. 2008; Wyrwich et al. 2009; Matza et al. 2010; Wyrwich et al. 2011), and further studies 
are required to ascertain the sensitivity of the instrument to detect changes across the range 
of efficacy measures available to evaluate symptoms associated with GAD (including 
commonly observed co-occurring conditions). The availability of Q-LES-Q(SF) data from the 
Quality of life, Utilization of services and Effects of STress (QUEST) study (Revicki et al. 
2008) provided the opportunity to contribute to existing evidence by further investigating 
the reliability, validity, and responsiveness of this instrument when administered via 
telephone as a measure of overall QOL and satisfaction related to various areas of 
functioning in patients with GAD. 
2. Methods 
This study was a post-hoc analysis of the QUEST study, which examined the treatment 
patterns, clinical and QOL outcomes, and direct and indirect costs associated with GAD in a 
US managed care organization; details of this study have been published elsewhere (Revicki 
et al. 2008). Briefly, this was a longitudinal study in which retrospective data were collected 
through an administrative claims database and prospective data were collected through 
telephone interviews. The study was approved by the institutional review board at Kaiser 
Permanente Northwest Region (KPNW Portland, Oregon), and complied with HIPAA 
requirements. 
2.1 Study procedures 
Patients who had 2 medical care encounters with diagnoses of GAD and/or anxiety state 
unspecified in the past 12 months (from 2003–2004) were recruited between June 2005 and 
June 2006. Eligible participants were identified through a review of the KPNW Data 
Warehouse. KPNW subsequently sent a memo and study fact sheet to the providers of each 
of these eligible participants asking for assistance in inviting their patients to participate. 
Interested potential participants, or those who did not invoke the initial refusal, were then 
contacted by telephone using a standardized screening script, during which time they were 
invited to participate in the study. 
Other inclusion criteria included: a confirmed DSM-IV diagnosis of GAD (300.02) and/or 
anxiety state unspecified (300.00) based on the Structured Clinical Interview for DSM-IV-TR; 
age ≥18 years; the ability to speak and read English; and completion of a written informed 
consent. There were no treatment requirements; patients were assigned the standard of care. 
Patients with a diagnosis of psychosis, bipolar disorder, organic psychotic disorder or 
mental retardation within the past 12 months or who had current cognitive impairment 
(memory loss and temporal disorientation demonstrated during a telephone contact or 
reported by a family member) were excluded from the QUEST study.  Retrospective data 
collection was conducted using administrative claims/encounter data to measure medical 
resource use and costs for the 12 months prior to the baseline survey, while prospective data 
were collected by following participants for a 6-month period, during which time 3 
telephone interviews were conducted (at baseline, 3-month follow-up [10–14 weeks after 
baseline] and 6-month follow-up [22–26 weeks after baseline]) to administer several 
questionnaires. For purposes of this secondary analysis, the study population was limited to 
subjects with prospective data collected through the telephone interviews.  
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2.2 Measures administered 
To evaluate overall QOL and satisfaction related to various areas of functioning, clinical 
symptoms associated with GAD, general health, fatigue, sleep, and disability, 
questionnaires administered in the study included the Q-LES-Q(SF), Patient Health 
Questionnaire Depression Questions (PHQ-8; (Kroenke and Spitzer 2002)), the Generalized 
Anxiety Disorder Questionnaire-IV (GAD-Q-IV (Newman et al. 2002)), the Structured 
Interview Guide for the Hamilton Anxiety Scale (SIGH-A (Hamilton 1959; Shear et al. 2001)), 
the Somatic Subscale of the Symptom Checklist (SCL-90 (Derogatis et al. 1974)), the Medical 
Outcomes Study 12-Item Short Form Health Survey, version 2 (SF-12v2 (Ware et al. 1996; 
Ware 2007)), Brief Fatigue Inventory (BFI (Mendoza et al. 1999)), Medical Outcomes Study 
Sleep Scale (MOS SS (Hays and Stewart 1992)), the Health Utilities Index Mark 2 
(HUI2)/Mark 3 (HUI3 (Feeny et al. 1996; Horsman et al. 2003; Statistics Canada and US 
National Center for Health Statistics 2004)), the Sheehan Disability Scale (SDS (Leon et al. 
1997)), and the Disability Days Questionnaire (DDQ (Broadhead et al. 1990; Revicki et al. 
1994); Table 1). These were administered at baseline and at 3- and 6-month intervals, with 
the exception of the SIGH-A, which was only administered at baseline and 3 months.  
 
Questionnaire Characteristics Scores 
Q-LES-Q(SF) 
 Participant-rated scale designed to measure the 
degree of enjoyment and satisfaction experienced 
by participants in their general activities of daily 
functioning 
 Composed of 14 general activity items (included 
in the score) and 2 additional items on medication 
satisfaction and overall life satisfaction item 
 Higher scores indicate greater enjoyment and 
satisfaction 
0 to 100 
PHQ 
 9-item scale consisting of the DSM-IV criteria used 
to diagnose MDD 
 Suicide item excluded in this study (PHQ-8) 
 Higher scores indicate greater depression severity 
0 to 24 
 
GAD-Q-IV 
 9-item self-reported revised diagnostic measure of 
GAD 
 Based on DSM-IV 
 Higher scores indicate greater anxiety severity 
0 to 12 
HAM-A  
(administered 
using SIGH-A) 
 Developed to evaluate the severity of anxiety 
symptoms 
 Administered via the Structured Interview Guide 
for the [SIGH-A], the developer-approved 
interview guides for the HAM-A 
 Higher scores indicate greater anxiety severity 
0 to 56 
SCL-90 
 Comprises 12 items that identify distress 
occurring from perceptions of bodily dysfunction 
 Higher scores indicate more somatic symptom 
distress 
0 to 48 
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Questionnaire Characteristics Scores 
SF-12 v2 
 PCS and MCS scores used in this study 
 Scores < 50 represent below-average physical 
health or mental health 
Norm-based 
scores with a 
mean of 50 and 
SD of 10* 
BFI 
 9 items plus an introductory question used to 
measure fatigue in cancer patients 
 A single item on the BFI used in this study, which 
asks participants to rate their worst level of 
fatigue during the past 24 hours 
0 (no fatigue) to 
10 (as bad as 
you can 
imagine) 
MOS SS 
 12-item self-reported questionnaire used to 
evaluate a participant’s sleep disturbances over 
the past 4 weeks 
 Sleep Problem Index II was used in this study 
 Higher scores indicate more sleep problems 
0 to 100 
HUI2/HUI3 
 Comprises the minimum number of questions (40 
items) required to classify the health status of a 
broad range of participants (age 5 +) 
 Recall period for each item is the previous 4 
weeks 
 Data on population norms are available for HU12 
and HU13 
0 (death) to 1.00 
(best possible 
health) 
SDS 
 Patient-reported 3-item questionnaire 
 Assesses mental health-related functional 
impairment 
 In this study, for participants who selected “not 
applicable” for the work item, the mean value of 
their social and family items were substituted in 
for the work item when deriving the total scale 
score 
0 to 30 
DDQ 
 Consists of 4 questions on missed work, late for 
work, bed disability and restricted activity days in 
the past 3 months due to GAD 
0 to 92 days 
(each item) 
BFI, Brief Fatigue Inventory; DDQ, Disability Days Questionnaire; GAD, Generalized Anxiety Disorder; 
GAD-Q-IV, Generalized Anxiety Disorder Questionnaire; HU12/HU13, Health Utilities Index; HAM-A, 
Hamilton Anxiety Scale; MDD, major depressive disorder; MOS SS, Medical Outcomes Study Sleep 
Scale; PHQ, Patient Health Questionnaire; Q-LES-Q(SF), Quality of Life Enjoyment and Satisfaction 
Questionnaire-Short Form; SIGH-A, Structured Interview Guide for the Hamilton Anxiety Scale; SCL-
90, Symptom Checklist;  SDS, Sheehan Disability Scale; SF-12, Short Form Health Survey.  
*US-based population 
Table 1. Questionnaires administered in the study (Hamilton 1959; Derogatis et al. 1974; 
Broadhead et al. 1990; Hays and Stewart 1992; Revicki et al. 1994; Feeny et al. 1996; Ware et 
al. 1996; Leon et al. 1997; Mendoza et al. 1999; Shear et al. 2001; Kroenke and Spitzer 2002; 
Newman et al. 2002; Horsman et al. 2003; Statistics Canada and US National Center for 
Health Statistics 2004; Ware 2007) 
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The Q-LES-Q(SF) total score was derived by summing scores from the first 14 Q-LES-Q(SF) 
items, each scored on a response scale ranging from 1 (very poor) to 5 (very good). The raw 
total score, which can range from 14 to 70, was then expressed as a percentage of the 
maximum (or % maximum) total score possible (ranging from 0–100) for ease of 
interpretation, with higher scores indicating greater enjoyment or satisfaction.  
2.3 Statistical analyses 
The eligible baseline sample (N = 296) was used for all baseline analyses. For 3- and 6-month 
analyses, those with at least 1 of these follow-up assessments were eligible for the respective 
analysis. Data analysis was conducted using SAS Version 9.1.3 (Copyright (c) 2002-2003 by 
SAS Institute Inc., Cary, NC, USA). 
2.3.1 Reliability  
Analyses of internal consistency from the baseline, 3-month, and 6-month data of the Q-LES-
Q(SF) using Cronbach’s alpha were conducted to ensure that the measure had strong 
internal consistency, where α >0.70 was indicative of a strong relationship among the 
measure’s items (Cronbach 1951). 
2.3.2 Validity 
Convergent validity was examined by constructing and reporting the appropriate 
correlation coefficient (Pearson for continuous variables or Spearman for ordinal variables) 
between the Q-LES-Q(SF) with the PHQ-8, GAD-Q-IV, HAM-A, SCL-90, PCS, MCS, BFI, 
MOS SS, HUI2, HUI3, SDS, and the DDQ using the baseline data, and again using the 3- and 
6-month data (with the exception of the HAM-A correlations calculated only at baseline and 
3 months) to gauge the strength of the cross-sectional relationships as weak (|r|< 0.30), 
moderate (0.30 ≤|r|< 0.60), or strong (|r| ≥0.60) (Hinkle et al. 1988). Moderate to strong 
relationships were hypothesized between the Q-LES-Q(SF) and all tested measures, except 
sleep and work-related measures, given the extreme nature of sleep and work when 
considered within overall QOL. The correlation of change scores across time (3 months – 
baseline and 6 months – baseline) were also analyzed to provide more support to the 
stability of the scale properties, and were hypothesized to be approximately the magnitude 
of the product of the cross-sectional correlations at each time point. 
Analysis of variance (ANOVA) tests comparing the mean values on the Q-LES-Q(SF) scores 
between the participant groups listed below were conducted to examine discriminant 
(known groups) validity. Both unadjusted and adjusted comparisons were conducted using 
age, gender, and baseline Q-LES-Q(SF) as covariates when 3- and 6-month data were used, 
and statistical significance was set at the P < .05 level. Mean scores were compared for: 
 Those with HAM-A scores ≤24 points and those with HAM-A scores >24 points (25–40) 
using the baseline scores (Matza et al. 2010). 
 Those with GAD-Q-IV scores ≥5.70 and those with scores <5.70 cutoff (Newman et al. 
2002). 
 Those with total scores of ≥10 on the PHQ-8 and those with scores <10 (Kroenke et al. 
2001). 
 Those with SDS total scores ≥5 and those with SDS scores <5 (Leon et al. 1997).  
 Those classified as asymptomatic (HAM-A ≤9); mild (HAM-A = 10–15), moderate 
(HAM-A = 16–24); or severe (HAM-A ≥25) using the baseline and 3-month data (Matza 
et al. 2010).  
www.intechopen.com
 
Different Views of Anxiety Disorders 
 
204 
 Those with PHQ-8 total scores in the categories of 0–4 (minimal), 5–9 (mild), 10–14 
(moderate), 15–19 (moderately severe) and 20–24 (severe) using the baseline, 3- and 6-
month data (Kroenke et al. 2001). 
Mean values for each of the groups were also compared to the Q-LES-Q(SF) norming values 
described in Schechter et al. (Schechter et al. 2007). In that investigation, controls were 
classified as never mentally ill (NMI); minor mental disorders only (MMD); currently not 
mentally ill (CNMI) with a history of mental illness that did not meet criteria for the MMD 
category; and currently mentally ill (CMI) with other than 1 specific phobia. Q-LES-Q(SF) 
mean scores were 81.8, 83.4, 78.4, and 72.7 for the NMI, MMD, CNMI, and CMI groups, 
respectively. 
ANOVA tests were also conducted comparing the mean values on the Q-LES-Q(SF) change 
scores (3 months – baseline and 6 months – baseline) between the participant change groups 
listed below to assess responsiveness. Both unadjusted comparisons and adjusted 
comparisons were conducted using age, gender, and baseline Q-LES-Q(SF) as covariates 
when change scores were used, and statistical significance was set at the P <.05 level.  
2.4 HAM-A change over time 
Changes in anxiety were assessed using changes in HAM-A scores over the 3 months of the 
study. First, HAM-A responders (≥50% reduction in HAM-A scores at 3 months) were 
compared with HAM-A non-responders. Second, HAM-A remitters (HAM-A scores ≤7 at 3 
months) were compared with HAM-A non-remitters. 
2.5 PHQ-8 change over time 
Changes in depression classification were assessed using changes in PHQ-8 levels over the 6 
months of the study. The mean change scores were calculated for those who were at the 
minimal (0–4) level at baseline and stayed at minimal at 6 months, minimal at baseline and 
changed to mild depression (5–9) at 6 months, minimal to moderate (10–14), and mild at 
baseline to moderately severe (15–19), and minimal at baseline to severe (20–24) at 6 months. 
This same mean change scores analysis was executed among persons at the mild, moderate, 
moderately severe and severe levels at baseline and classified the change over the 6-month 
period to 1 of 5 PHQ-8 groupings (minimal, mild, moderate, moderately severe, and severe). 
3. Results 
Of the 296 participants in this study, 72.3% were female, with a mean age of 47.6 years 
(Table 2). The majority of participants identified themselves as white (92.9%), had at least 
some college education (75.3%), and most were employed on a full- or part-time basis (42.9 
and 13.5%, respectively). At baseline, PHQ-8 mean scores corresponded with moderate 
depression, averaging 11.0 (possible range: 0–24; higher scores indicate greater depression 
severity), which is near the median of 12.5 reported in another GAD patient population 
(Kroenke et al. 2007). HAM-A scores indicated moderate levels of anxiety, averaging 16.7 
(possible range: 0–56; higher scores indicate greater anxiety severity), which was lower than 
the range of 22.6–25.8 reported by Endicott et al. (Endicott et al. 2007) and the average of 
25.54 reported by Wyrwich et al. in another GAD patient population (Wyrwich et al. 2009). 
Mean SDS scores (13.7; possible range: 0–30; higher scores indicate greater impairment) 
were close to those seen in a primary care sample of GAD patients with an SDS score 
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Characteristic N = 296 
Age, y, mean (SD) 47.6 (13.7) 
Female n (%) 214 (72.3) 
White n (%) 275 (92.9) 
Education n (%)  
Elementary/primary school 10 (3.4) 
Secondary/high school 62 (20.9) 
Some college 113 (38.2) 
College degree 70 (23.6) 
Postgraduate degree 40 (13.5) 
Missing 1 (0.3) 
Employment status n (%)  
Employed, full time 127 (42.9) 
Employed, part time 40 (13.5) 
Homemaker 20 (6.8) 
Student 5 (1.7) 
Unemployed 26 (8.8) 
Retired 52 (17.6) 
Disabled 19 (6.4) 
Other 6 (2.0) 
Missing 1 (0.3) 
Baseline scores, mean (SD)  
PHQ-8 11.0 (5.6) 
GAD-Q-IV 6.0 (3.0) 
HAM-A 16.7 (7.2) 
SCL-90 11.1 (7.3) 
SF-12v2 – PCS 45.0 (10.3) 
SF-12v2 – MCS 43.1 (8.3) 
BFI 6.2 (2.3) 
MOS SS (Sleep Quantity) 7.0 (1.8) 
MOS SS (Sleep Problem Index II) 46.9(19.3) 
HUI2 0.5 (0.2) 
HUI3 0.5 (0.3) 
SDS 13.7 (7.7) 
DDQ (missed work days) 5.7 (13.8) 
Q-LES-Q(SF) 55.8 (16.5) 
Abbreviations: SD, standard deviation; PHQ-8, Patient Health Questionnaire; GAD-Q-IV, Generalized 
Anxiety Disorder Questionnaire-IV; HAM-A, Hamilton Anxiety Scale-Anxiety; SCL-90, Symptom 
Checklist; SF-12v2 – PCS, SF-12 Health Survey version 2 – Physical Component Summary; SF-12v2 – 
MCS, SF-12 Health Survey version 2 – Mental Component Summary; BFI, Brief Fatigue Inventory; MOS 
SS, Medical Outcomes Study Sleep Scale; HUI2/3, Health Utilities Indices, Mark 2/3; SDS, Sheehan 
Disability Scale; DDQ, Disability Days Questionnaire; Q-LES-Q(SF), Quality of Life Enjoyment and 
Satisfaction Questionnaire-Short Form  
Table 2. Demographic characteristics for the generalized anxiety disorder patient sample 
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exceeding the cutoff of 5 or greater, which is an indicator of increased risk of mental health 
impairment (mean = 13.95) (Leon et al. 1997), and lower than the range of 14.3–17.5 seen at 
baseline in 3 independent studies among GAD patients (Endicott et al. 2007). Additionally, 
SF-12v2 PCS scores averaged 45.0 (possible range: 0–100; scores below 50 represent below 
average physical health), and SF-12v2 MCS scores averaged 43.1 (possible range: 0–100; 
scores below 50 represent below average mental health).  
3.1 Reliability 
Reliability of the Q-LES-Q(SF) at baseline, 3, and 6 months was excellent, with Cronbach’s 
alphas of 0.88, 0.90, and 0.90, respectively. These reliability estimates 1) exceeded the 
recommended cutoff of 0.70; 2) demonstrated little change over time in the correlations of the 
Q-LES-Q(SF) items with each other; and 3) support the 1-factor structure of the Q-LES-Q(SF). 
3.2 Validity 
3.2.1 Construct validity  
Using Pearson or Spearman correlations (as appropriate), convergent validity was examined 
between the Q-LES-Q(SF) and the PHQ-8, GAD-Q-IV, HAM-A, PCS, MCS, SDS, DDQ, MOS 
SS, SCL-90, BFI, HUI2, and HUI3 using the baseline data, and again using the 3- and 6-
month data to gauge the strength and stability of the baseline relationships (Table 3). With 
the exception of correlations with the MOS SS at baseline, and the DDQ late for work at 3 
months, all Q-LES-Q(SF) correlations were statistically significant at the P<.05 level. 
Measures of anxiety (GAD-Q-IV, HAM-A) demonstrated moderate correlations (with 
moderate defined as 0.30 < |r| < 0.60) with values that were fairly consistent at baseline, 3 
months and 6 months. The Q-LES-Q(SF) was most highly correlated with the PHQ-8, a 
measure of depression, with correlations of –0.69 at baseline, –0.73 at 3 months, and –0.72 at 
6 months. Measures of general health (PCS, MCS) had moderate correlations and fairly 
consistent values at baseline, 3 months, and 6 months. As expected, the MCS had a higher 
correlation with the Q-LES-Q(SF) compared with the PCS. Measures of disability (SDS, DDQ 
bed days and kept from usual activity days) showed moderate correlations and consistency 
at baseline, 3 months, and 6 months. Sleep quantity, as measured through 1 MOS SS item, 
demonstrated a low correlation with the Q-LES-Q(SF) at baseline (r = 0.08), 3 months (r = 
0.17), and 6 months (r = 0.13); however, the Sleep Problem Index II (also measured through 
the MOS SS) demonstrated moderate correlations of –0.49, –0.56, and –0.50 with the Q-LES-
Q(SF) at baseline, 3 months, and 6 months, respectively. Distress due to perceptions of 
bodily dysfunction (SCL-90) and fatigue (BFI) also demonstrated moderate correlations and 
fairly consistent values at baseline, 3 months, and 6 months. Interestingly, data for measures 
of health utility (HUI2, HUI3) showed that the HUI3 demonstrated strong correlations (r 
≥0.60) with the Q-LES-Q(SF) at 3 and 6 months, while the HUI2 came close to, but did not 
achieve, this level of association with the Q-LES-Q(SF). Change score correlations supported 
the stability of the scale properties (data not shown), and slightly exceeded the hypothesized 
magnitude of the product of the cross-sectional correlations at each time point. 
3.2.2 Known groups validity of the Q-LES-Q(SF)  
Using a severe anxiety definition of HAM-A scores ≥ 24 (Matza et al. 2010), statistically 
significant (P<.001) differences in Q-LES-Q(SF) unadjusted mean scores between anxiety 
severity groups were observed at baseline and at 3 months (58.50 vs. 40.83 and 62.11 vs. 
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38.65, respectively), with higher Q-LES-Q(SF) mean scores observed in the less severe group 
(Table 4). Moreover, these differences between the mean scores were greater than 1 standard 
deviation (SD) at both time points. Analysis using adjusted scores demonstrated similar 
mean scores and differences between mean scores in these severity groups that were also 
greater than 1 SD. 
 
Measure 
Baseline 3 Months 6 Months 
Correlation* N Correlation* N Correlation* N 
PHQ-8 –0.69 296 –0.73 246 –0.72 251 
GAD-Q-IV –0.43 296 –0.50 246 –0.48 251 
HAM-A –0.59 296 –0.60 246 b b 
SCL-90 –0.50 296 –0.54 246 –0.58 251 
SF-12v2 – PCS 0.37 296 0.37 246 0.42 251 
SF-12v2 – MCS 0.56 296 0.65 246 0.62 251 
BFI –0.45 295 –0.48 246 –0.50 251 
MOS SS (Sleep Quantity) 0.08 296 0.17 246 0.13 251 
MOS SS (Sleep Problem 
Index II) 
–0.49 296 –0.56 246 –0.50 251 
HUI2 0.48 262 0.59 209 0.59 223 
HUI3 0.54 263 0.64 211 0.60 230 
SDS –0.54 296 –0.64 246 –0.55 251 
DDQa-Missed work –0.25 172 –0.30 143 –0.27 147 
DDQa-Late for work –0.25 171 –0.07 143 –0.26 147 
DDQa-Bed days –0.32 294 –0.34 245 –0.31 251 
DDQa-Kept from usual 
activities 
–0.36 296 –0.38 245 –0.52 250 
*All correlations >0.08 were significant at the p<0.05 level.  
aDDQ Recall period was over the past 4 weeks. 
bHAM-A measured only at baseline and 3 months. 
Abbreviations: Q-LES-Q(SF), Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; 
PHQ-8, Patient Health Questionnaire; GAD-Q-IV, Generalized Anxiety Disorder Questionnaire-IV; 
HAM-A, Hamilton Anxiety Scale-Anxiety; SCL-90, Symptom Checklist; SF-12v2 – PCS, SF-12 Health 
Survey version 2 – Physical Component Summary; SF-12v2 – MCS, SF-12 Health Survey version 2 – 
Mental Component Summary; BFI, Brief Fatigue Inventory; MOS SS, Medical Outcomes Study Sleep 
Scale; HUI2/3, Health Utilities Indices, Mark 2/3; SDS, Sheehan Disability Scale; DDQ, Disability Days 
Questionnaire 
Table 3. Correlations of the Q-LES-Q(SF) with other clinician-reported and patient-reported 
outcomes in the QUEST study 
Another known groups comparison of Q-LES-Q(SF) mean scores employed a different 
anxiety measure, the GAD-Q-IV, and a cutoff score of 5.70, a value that had previously been 
demonstrated to have optimal sensitivity and specificity for identifying individuals with 
GAD (Newman et al. 2002). Mean adjusted and unadjusted Q-LES-Q(SF) scores were similar 
(Table 4), with those above the 5.70 threshold reporting higher Q-LES-Q(SF) unadjusted 
mean scores of 61.12, 64.53 and 64.56 at baseline, 3 months, and 6 months, respectively, 
while those with scores below the threshold had unadjusted mean scores of 49.93, 49.66, and 
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49.48 at the baseline, 3-month and 6-month periods, with all differences between the 2 
groups at the 3 time points nearing, if not exceeding, the 1 SD threshold. All of these groups’ 
mean Q-LES-Q(SF) scores were much lower than NMI, MMD, CNMI, and CMI norming 
subgroups (Schechter et al. 2007), indicating the important burden on overall QOL and 
satisfaction related to various areas of functioning among patients with GAD. 
 
Time 
HAM-A ≤24 
N, Mean (SD) 
HAM-A >24 
N, Mean (SD) 
P Valuea 
Baseline 250, 58.50 (15.0) 46, 40.83 (16.4) < .0001 
3 month 216, 62.11 (15.5) 31, 38.65 (14.8) < .0001 
Time 
GAD-Q-IV <5.70 
N, Mean (SD) 
GAD-Q-IV ≥5.70 
N, Mean (SD) 
P Valuea 
Baseline 154, 61.12 (14.4) 142, 49.93 (16.6) < .0001 
3 month 156, 64.53 (14.8) 90, 49.66 (17.3) < .0001 
6 month 162, 64.56 (14.6) 88, 49.48 (16.1) < .0001 
Time 
PHQ-8 <10 
N, Mean (SD) 
PHQ-8 ≥10 
N, Mean (SD) 
P Valuea 
Baseline 132, 65.64 (11.9) 164, 47.79 (15.3) < .0001 
3 month 142, 67.54 (13.5) 105, 47.85 (15.3) < .0001 
6 month 159, 66.77 (13.1) 92, 46.22 (14.1) < .0001 
Time 
SDS <5.0 
N, Mean (SD) 
SDS ≥5.0 
N, Mean (SD) 
P Valuea 
Baseline 40, 68.98 (15.4) 256, 53.68 (15.7) < .0001 
3 month 56, 72.75 (14.4) 190, 55.06 (16.0) < .0001 
6 month 65, 71.38 (13.1) 185, 54.98 (15.8) < .0001 
aP Values for analysis of variance comparison. 
Abbreviations: Q-LES-Q(SF), Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; 
HAM-A, Hamilton Anxiety Scale-Anxiety; GAD-Q-IV, Generalized Anxiety Disorder Questionnaire-IV; 
PHQ-8, Patient Health Questionnaire; SDS, Sheehan Disability Scale; SD, standard deviation 
Table 4. Unadjusted Q-LES-Q(SF) mean scores for patients using recommended cutoff scores 
Known groups analysis by severity group was also conducted using the PHQ-8. Using a 
minimal or mild depressive-state threshold of PHQ-8 scores <10, statistically significant 
(P<.0001) differences in Q-LES-Q(SF) unadjusted mean scores between those with 
minimal/mild depression compared with more severe depression were observed at 
baseline, 3 months, and 6 months (65.64 vs. 47.79, 67.54 vs. 47.85, and 66.77 vs. 46.22, 
respectively; P<.0001 for all comparisons), with higher Q-LES-Q(SF) mean scores 
consistently observed in the minimal/mild group (Table 4). Differences in mean scores 
between those with minimal/mild depression and those with more severe depression were 
greater than 1 SD at all 3 time points. Adjusted scores were similar to unadjusted scores and 
demonstrated equal levels of statistical significance. Again, all of these groups’ mean Q-LES-
Q(SF) scores were much lower that those found among any Q-LES-Q(SF) norming 
subgroups (Schechter et al. 2007). 
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Additional known groups validity of the Q-LES-Q(SF) was demonstrated when known groups 
based on disability status with an SDS cutoff score of 5.0 were evaluated. Subjects with SDS 
scores ≥5.0 were classified as at least moderately impaired, and had unadjusted mean Q-LES-
Q(SF) scores of 53.68, 55.06, and 54.98 at the baseline, 3-month, and 6-month periods compared 
with subjects with less than moderate impairment, who had mean scores of 68.98, 72.75, and 
71.38 for the same periods (Table 4). Differences in mean scores between those with moderate 
or greater impairment and those with less than moderate impairment exceeded 1 SD at the 3- 
and 6-month periods, with statistically significant differences at all 3 time points (P<.0001). 
Adjusted scores remained similar to the unadjusted scores, and demonstrated the same levels 
of statistical significance (P<.0001), and all of these groups’ mean Q-LES-Q(SF) scores were 
much lower than any control subgroups (Schechter et al. 2007).  
Unadjusted Q-LES-Q(SF) mean scores by 4 more refined HAM-A score severity groups (Fig. 
1) and PHQ-8 severity levels (Fig. 2) were also similar to adjusted Q-LES-Q(SF) mean scores, 
with clear separation (>1/2 SD) of the sample in each score group for each time point when 
compared with adjacent groups (with the exception of the moderately severe vs. severe 
PHQ-8 comparison at 3 months). Statistically significantly (P<.0001) lower Q-LES-Q(SF) 
scores were observed as anxiety symptom severity increased, with pairwise comparisons 
that were statistically significant at baseline and 3-month follow-up (all unadjusted P<.01; 
all adjusted P<.001).  
 
 
Abbreviations: Q-LES-Q(SF), Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; 
HAM-A, Hamilton Anxiety Scale-Anxiety  
Fig. 1. Unadjusted Q-LES-Q(SF) mean scores by HAM-A score groups at baseline, month 3 – 
multiple comparisons between different HAM-A groups at each time point 
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Abbreviations: Q-LES-Q(SF), Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; 
PHQ-8, Patient Health Questionnaire  
Fig. 2. Q-LES-Q(SF) mean scores by PHQ-8 score groups at baseline, month 3 and month 6 – 
multiple comparisons between different PHQ-8 groups at each time point 
3.2.3 Responsiveness of the Q-LES-Q(SF)  
We conducted 3 different analyses to investigate the ability of the Q-LES-Q(SF) scores to 
detect important changes in this population of persons with GAD. T-tests compared 
responders with non-responders using 2 different criteria: HAM-A responders (patients 
who had at least a 50% reduction in their HAM-A scores between baseline and the 3-month 
follow-up), and HAM-A remitters (patients whose HAM-A scores decreased to levels at or 
below 7 points). In the HAM-A responders analysis, responders (n=229) had a mean level of 
improvement of 4.31 points on the Q-LES-Q(SF) over 3 months, compared with mean 
declines of 8.19 Q-LES-Q(SF) points for non-responders (n=16; P=.0011). HAM-A remitters 
(n=40) demonstrated a mean improvement of 10.85 points compared with the mean change 
of 2.06 points among non-remitters (n=205; P=.0006).  
A third analysis tested the ability of the Q-LES-Q(SF) scores to detect a change over 6 
months using change categories defined by PHQ-8 change scores (Table 5). The bolded 
values in this table represent the mean change scores for patients who remained in the same 
PHQ-8 depressive category over the course of the study; on average participants who 
remained in the minimal, mild, or moderate depression categories demonstrated very little 
change over time (≤2 points). For those who demonstrated a small improvement in 
depressive symptoms, as demonstrated by movement to a better adjacent category 
(italicized mean values), mean change levels ranged from 4.4 points (moderate  mild) to 
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10.8 points (severe  moderately severe). With few exceptions, all categories in Table 5 
demonstrated a strong trend of decreasing Q-LES-Q(SF) mean change scores from baseline 
as depressive symptom categories worsened (left to right). 
 
Baseline 
Depression 
Category 
(PHQ-8 Score) 
Mean (SD), N 
6-Month Depression Category (PHQ-8 Score) 
Minimal (0–4) Mild (5–9) 
Moderate  
(10–14) 
Moderately 
Severe (15–
19) 
Severe (20–24) 
Minimal(0–4) –1.6 (10.1), 19 –4.3 (7.3), 11   –51.0 (n/a ), 1 
Mild (5–9) 9.2 (13.7), 33 –1.5 (11.5), 35 –0.2 (14.4), 14 –23.0 (12.7), 2  
Moderate  
(10–14) 
18.4 (10.4), 11 4.4 (12.3), 26 -1.8 (14.6), 22 –21.3 (7.1), 4 –10.7 (5.0), 3 
Moderately 
Severe (15–19) 
20.8 (15.1), 5 16.0 (14.8), 13 7.8 (12.6), 12 –7.2 (16.0), 11 0.0 (12.7), 2 
Severe (20–24) 39.3 (26.0), 4 36.0 (7.1), 2 11.0 (7.9), 3 10.8 (12.3), 12 3.7 (8.3), 6 
Bolded values represent mean change levels for patient with GAD who stayed at the same depressive 
level over 6 months. 
Italicized values represent mean change levels for patient with GAD who improved by 1 depressive 
level over 6 months. 
Abbreviations: Q-LES-Q(SF), Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; 
PHQ-8, Patient Health Questionnaire  
Table 5. Mean change Q-LES-Q(SF) scores, standard deviation and N by depression change 
categories over 6 months using PHQ-8 scores for classifying depression  
4. Discussion 
There is a critical need for psychometrically sound measures of mental health–related 
impairment (Leon et al. 1997). This study investigated the reliability, validity, 
responsiveness, and interpretation of the Q-LES-Q(SF) scores among the members of a 
group-model health care delivery system with GAD. Our findings strongly support the 
psychometric properties of the Q-LES-Q(SF) and give additional support for its use as a PRO 
in this mental health condition. Reliability was consistently robust, with Cronbach’s alpha at 
0.88 or higher at all time points (baseline, 3 months, and 6 months). High correlations (r 
≥0.60) with other measures of anxiety and depression (PHQ-8 and HAM-A) at all time 
points, as well as the HUI3 at 3 and 6 months and SDS at the 3-month time point, support 
the construct validity of the measure. Although the Q-LES-Q(SF) scores demonstrated high 
correlations with these mental health severity measures, it is also important to note that the 
Q-LES-Q(SF) is not redundant with them; that is, there is at most 53% shared variance (–
0.732) with the PHQ-8 at the 3-month measurement. Moreover, moderate (0.30 < |r| < 0.60) 
correlations with other measures associated with GAD (GAD-Q-IV, SCL-90, SF-12V2 PCS 
and MCS, BFI, HUI2, and disability days for missed work, bed days or kept from usual 
activities) were demonstrated at 1 or more of the time points.  
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In the current study, the Q-LES-Q(SF) mean baseline score was 55.8, and similar to the 
baseline mean score of 51.2 reported by participants across three GAD clinical trials 
(Wyrwich et al. 2009). A number of correlations between the Q-LES-Q(SF) and other 
outcomes detected in the current analysis are also consistent with previous studies, namely 
the low to moderate correlation with sleep measures, which mirrors that observed with the 
Pittsburgh Sleep Quality Index in other GAD samples (Wyrwich et al. 2009), and the 
moderate correlation between Q-LES-Q(SF) and HAM-A reported in 2 other studies (r = –
0.45 (Endicott et al. 2007) and r = –0.36 (Wyrwich et al. 2009)). 
Known groups validity found an effect size difference of 1 or more SDs between relevant 
groups using standard thresholds for classifying persons with GAD with HAM-A, PHQ-8, 
GAD-Q-IV, and SDS scores. Moreover, most of the relevant dichotomous cut points for the 
HAM-A (cut point of 24), PHQ (cut point of 10) and GAD-Q-IV (cut point of 5.70) yielded 
mean scores at similar levels, where the group with better health had a mean score of about 
60–70 points, and the group with worst health averaged in the 40- to 50-Q-LES-Q(SF) point 
range. As seen earlier, all of these groups’ mean Q-LES-Q(SF) scores were much lower than 
those found among any of the relevant subgroups of normal controls investigated by 
Schechter et al. (Schechter et al. 2007). Additional analyses comparing the change scores for 
HAM-A remitters and responders over 3 months, and PHQ-8 improvements in depressive 
states classifications over 6 months, yielded mean change scores in a consistent range 
corresponding to the responder threshold level established for persons with GAD in prior 
treatment studies. 
In prior work we determined that the mean Q-LES-Q(SF) score change was 6.80 in patients 
experiencing minimal improvement reported by their clinicians using the Clinical Global 
Impressions-Improvement of Illness at 8 weeks (Wyrwich et al. 2009). In this post-hoc 
analysis, mean Q-LES-Q(SF) changes for the HAM-A responders and remitters were 4.31 
and 10.85 points over 3 months, respectively. Similarly, small but possibly important 
changes on the PHQ-8 categories yielded mean change levels that ranged from 4.4–10.8 
points over 6 months of observation, and these additional analyses appear to support the 
6.80 point responder threshold using the novel anchors available in these data. 
In considering potential methodological limitations of this study, it should be noted that 
retrospective data were collected through an administrative claims database, which may be 
subject to bias due to the inability to ensure coding accuracy. The fact that the Q-LES-Q(SF) 
does not represent a GAD-specific patient-reported measure of QOL is another potential 
limitation. However, the validity of the Q-LES-Q has been convincingly demonstrated 
across psychiatric disorders (Endicott et al. 1993; Ritsner et al. 2005; Rossi et al. 2005; 
Endicott et al. 2006; Schechter et al. 2007; Mick et al. 2008; Revicki et al. 2008). As an 
exploratory secondary data analysis, no method to control for the probability of family-wise 
type I error due to multiple comparisons planned was incorporated beyond Scheffe’s 
method as mentioned for overall comparisons. Nonetheless, P-values were consistently less 
than .01 for all significant comparisons reported, and therefore, reduce the likelihood that 
any differences were the result of Type 1 error. Finally, questionnaires used in this study 
were administered via telephone. Previous psychiatric studies have successfully employed 
the telephone interview method for the administration of questionnaires (Larson et al. 2008; 
Kroenke et al. 2009; Simon et al. 2009). Cacciola et al. suggested caution in assuming 
comparability between telephone and in-person Structured Clinical Interview for DSM-III 
(SCID) Diagnosis based on telephone data collected from 41 college aged men with very 
limited psychiatric diagnoses (Cacciola et al. 1999); however, subjects in the QUEST study 
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were diagnosed with GAD by their physicians prior to study entry and the SIGH-A has 
demonstrated strong reliability among patients with GAD (Shear et al. 2001).  
Although our focus in this investigation was on the psychometric properties of the Q-LES-
Q(SF), it is important to note that these results also demonstrate the significant impairment 
to psychological well-being, physical functioning, work productivity, and additional 
disability associated with GAD. Despite estimated prevalence rates for GAD ranging from 
2.7–5.4% in the general population in the United States and Europe (Massion et al. 1993; 
Kessler et al. 1999; Wittchen et al. 2000; Kessler et al. 2001; Henning et al. 2007), diagnosis 
and subsequent treatment are often missed (Kessler et al. 2005; Ruscio et al. 2007). Given the 
impact of this condition on health status and overall QOL (Revicki et al. 2008), this post-hoc 
study shows that Q-LES-Q(SF) constitutes a short, focused and psychometrically sound PRO 
that complements a range of outcome measures evaluating symptoms associated with 
patients with GAD seeking treatment for this condition. 
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